Vyleesi (Bremelanotide) Complete Drug-Drug Interaction Profile

How Bremelanotide Works and Why It Matters for Interactions

Bremelanotide is a cyclic heptapeptide that activates melanocortin-4 receptors (MC4R) in the central nervous system, triggering downstream dopaminergic and oxytocinergic signaling that modulates sexual desire. The drug was approved in June 2019 based on two phase III RECONNECT trials (N=1,247 combined), which demonstrated statistically significant improvements in desire and reductions in distress compared with placebo over 24 weeks 1.

Understanding its interaction profile requires separating two distinct pathways: pharmacokinetic effects (what the body does to the drug and co-administered agents) and pharmacodynamic effects (overlapping physiologic actions with other medications). Because bremelanotide bypasses hepatic first-pass metabolism entirely through subcutaneous delivery, classic CYP450 interactions do not apply. The FDA-approved prescribing information identifies gastric motility suppression and transient cardiovascular changes as the two clinically relevant interaction mechanisms.

The peptide's short half-life of 2.7 hours means most pharmacodynamic risks are confined to a narrow post-dose window. That feature distinguishes bremelanotide from daily-dosed HSDD treatments like flibanserin, where steady-state drug levels create continuous interaction exposure 2.

The Gastric Emptying Effect: Oral Drug Absorption Changes

Bremelanotide activates MC4 receptors in the brainstem and enteric nervous system, producing a dose-dependent slowing of gastric emptying. This is the single most clinically significant pharmacokinetic interaction in the Vyleesi label.

In a dedicated crossover pharmacokinetic study, bremelanotide 1.75 mg reduced the C_max of a co-administered acetaminophen probe (used as a gastric emptying marker) by approximately 60% and delayed T_max by roughly 1 hour 3. Total absorption (AUC) was not significantly affected, meaning the same total amount of drug eventually reaches the bloodstream, but peak concentrations drop substantially.

For most medications, this delay is clinically irrelevant. A statin taken in the evening or a maintenance antihypertensive will still reach therapeutic systemic exposure. The concern applies specifically to drugs where rapid onset or peak concentration is the therapeutic driver.

Drugs requiring clinical attention with timing:

• Rescue analgesics (ibuprofen, sumatriptan, acetaminophen): slower absorption means delayed onset of pain or migraine relief. Patients should take these at least 1 hour before bremelanotide or wait until the gastric slowing effect resolves (approximately 4 to 6 hours post-dose).
• Short-acting benzodiazepines (alprazolam, lorazepam): C_max-dependent sedation onset may be delayed, potentially prompting patients to re-dose. Counsel against taking supplemental doses.
• Oral naltrexone: the FDA label specifically flags this combination. Naltrexone 50 mg C_max fell 38% when co-dosed with bremelanotide. Because naltrexone's opioid-blocking effect is threshold-dependent, this reduction may create a window of incomplete receptor occupancy.

Drugs with wide therapeutic windows taken on maintenance schedules (SSRIs, levothyroxine, oral contraceptives at steady state) are unlikely to produce clinically meaningful changes from a single delayed-absorption event.

Oral Contraceptives: A Specifically Studied Combination

Because bremelanotide's target population is premenopausal women, the FDA required a dedicated drug-interaction study with a combined oral contraceptive (ethinyl estradiol/norethindrone). The results showed reduced C_max for both ethinyl estradiol (reduction of approximately 23%) and norethindrone (approximately 20%) with a delay in T_max of 0.5 to 1 hour 3.

AUC values remained within bioequivalence bounds. Contraceptive efficacy depends on sustained hormonal suppression of ovulation across a 24-hour dosing cycle, not on peak concentration from a single dose. The FDA concluded that no dose adjustment or timing separation is needed for combined oral contraceptives when used with bremelanotide 3.

Progestin-only pills ("mini-pills") were not specifically studied. Because their contraceptive mechanism relies more heavily on consistent daily peak progestin levels, clinicians prescribing both agents should counsel patients to separate dosing by at least 2 hours as a precaution.

Cardiovascular Pharmacodynamic Interactions

Bremelanotide produces a transient increase in blood pressure: mean systolic rises of 2 to 3 mmHg and diastolic rises of 1 to 2 mmHg, peaking 2 to 3 hours after injection and returning to baseline by 6 to 12 hours. Heart rate decreases by 2 to 5 beats per minute reflexively 1. The RECONNECT trials excluded women with uncontrolled hypertension (defined as blood pressure above 140/90 mmHg), and the drug carries a labeled precaution for cardiovascular disease 4.

Antihypertensive combinations to monitor:

• Alpha-blockers (prazosin, doxazosin): bremelanotide's pressor effect directly opposes the mechanism of alpha-1 antagonism. In women taking alpha-blockers for off-label indications (PTSD nightmares, Raynaud phenomenon), the clinical impact is likely minimal given bremelanotide's small pressor magnitude. No dose adjustment is required, but blood pressure checks are reasonable in the first few co-administration cycles.
• Centrally acting agents (clonidine, methyldopa): MC4R activation and alpha-2 agonism both modulate sympathetic outflow from the brainstem. Theoretical bidirectional interference exists, though no clinical reports of adverse events have been published.
• ACE inhibitors and ARBs: no pharmacodynamic conflict. These agents work via the renin-angiotensin system and would not be affected by a transient catecholamine-mediated pressor response.

Vasoconstrictor combinations carrying higher risk:

• Triptans (sumatriptan, rizatriptan): 5-HT1B/1D agonists produce coronary and cerebral vasoconstriction. Adding bremelanotide's pressor effect during an active migraine could theoretically amplify cardiovascular stress. No formal study exists, but the combined use should trigger a risk-benefit discussion with the prescriber.
• Ergot alkaloids (ergotamine, dihydroergotamine): potent vasoconstrictors with prolonged duration of action. Concomitant use with bremelanotide is not recommended per clinical pharmacology principles, even though no specific warning appears in the label.
• Sympathomimetic decongestants (pseudoephedrine, phenylephrine): additive pressor effects are predictable. Women using bremelanotide who take OTC cold medications should be aware of the potential for headache, flushing, or transient hypertensive episodes.

Melanocortin Pathway Crosstalk: Naltrexone and Opioid Interactions

The melanocortin and endogenous opioid systems share extensive crosstalk in the hypothalamus. MC4R activation stimulates alpha-melanocyte-stimulating hormone (alpha-MSH) pathways that are tonically inhibited by beta-endorphin signaling through mu-opioid receptors. This bidirectional regulation creates a pharmacologically relevant interaction surface.

Naltrexone: the most clinically important interaction in this category. Naltrexone (used at 50 mg for alcohol/opioid use disorders and at 4.5 mg as low-dose naltrexone) blocks mu-opioid receptors, removing the tonic inhibition of melanocortin signaling. Co-administration with bremelanotide could theoretically amplify MC4R-mediated effects, including nausea, flushing, and blood pressure changes. The FDA label notes that the combination has not been adequately studied and recommends caution 4. The pharmacokinetic interaction (38% C_max reduction of naltrexone) compounds this pharmacodynamic concern.

The Endocrine Society's 2019 commentary on melanocortin-targeted therapeutics noted that "melanocortin-opioid crosstalk in the arcuate nucleus means that drugs modifying either system should be co-prescribed with awareness of reciprocal amplification or attenuation" 5.

Full opioid agonists (oxycodone, morphine, hydrocodone): opioids suppress melanocortin tone. Co-administration with bremelanotide may blunt bremelanotide's efficacy through mu-receptor-mediated inhibition of MC4R downstream signaling. No formal interaction study exists, but women taking chronic opioid therapy for pain should be counseled that Vyleesi response may be attenuated.

Buprenorphine/naloxone (Suboxone): partial mu-agonist activity from buprenorphine combined with naloxone's antagonism creates a complex pharmacodynamic environment. Prescribers should consider this combination a relative precaution until clinical data emerge.

CYP450 and Transporter-Based Interactions: Why They Don't Apply

Bremelanotide is a synthetic peptide degraded by non-specific peptidases in the plasma and tissues, not by cytochrome P450 enzymes. In vitro studies submitted to the FDA demonstrated no inhibition or induction of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 times the expected clinical exposure 3.

The drug is not a substrate or inhibitor of P-glycoprotein (P-gp), OATP1B1, OATP1B3, OCT2, OAT1, OAT3, BCRP, MATE1, or MATE2-K. With 21% plasma protein binding, displacement interactions with highly bound drugs (warfarin, phenytoin) are not expected 3.

This clean metabolic profile is a direct consequence of bremelanotide's peptide chemistry. Unlike flibanserin, which is extensively metabolized by CYP3A4 and carries a boxed warning for alcohol interaction and strong CYP3A4 inhibitor co-use 2, bremelanotide can be co-administered with azole antifungals, macrolide antibiotics, HIV protease inhibitors, and other CYP3A4 substrates or inhibitors without dose modification.

Alcohol and Recreational Substance Interactions

The FDA did not require a formal alcohol interaction study for bremelanotide, and the prescribing label carries no alcohol warning. This contrasts sharply with flibanserin's boxed warning mandating complete alcohol avoidance due to severe hypotension and syncope risk 2.

Bremelanotide's cardiovascular mechanism does suggest caution with heavy alcohol intake, though. Alcohol produces vasodilation and tachycardia; bremelanotide produces a transient pressor response and reflex bradycardia. The physiologic result of combining these effects is unpredictable, and nausea (reported in 40% of bremelanotide users in RECONNECT 1) may worsen with concurrent alcohol consumption.

Cannabis (THC) has no known interaction with melanocortin receptors. Cocaine and amphetamine-type stimulants are potent sympathomimetics and would theoretically amplify bremelanotide's pressor effect. The clinical significance is not established, but prescribers treating women with disclosed stimulant use should document the additive cardiovascular risk.

Psychiatric Medication Interactions

Many women with HSDD are concurrently treated for depression or anxiety. SSRIs, SNRIs, and bupropion are among the most commonly co-prescribed drug classes.

SSRIs and SNRIs (sertraline, escitalopram, venlafaxine, duloxetine): no pharmacokinetic interaction exists (bremelanotide does not affect CYP2D6 or CYP2C19 activity). Pharmacodynamically, serotonergic drugs are themselves associated with reduced libido, which may diminish bremelanotide's clinical benefit. The RECONNECT trials permitted SSRI/SNRI use at stable doses, and subgroup analyses did not show differential efficacy, though the subgroups were small 1. There is no serotonin syndrome risk: bremelanotide does not affect serotonin reuptake, release, or receptor binding.

Bupropion: acts via norepinephrine and dopamine reuptake inhibition. Because bremelanotide's MC4R activation increases dopaminergic tone in the medial preoptic area, a theoretical additive pro-sexual effect exists. No adverse interaction has been identified, and some clinicians consider bupropion a complementary agent for HSDD.

Flibanserin (Addyi): co-prescribing two FDA-approved HSDD treatments has not been studied. Flibanserin's 5-HT1A agonist and 5-HT2A antagonist activity operates through a different mechanism than MC4R agonism. The primary concern is additive hypotension (flibanserin lowers blood pressure) opposing bremelanotide's pressor response, creating hemodynamic unpredictability. The FDA label does not address this combination. Until data emerge, co-prescription is not recommended.

Nausea Management and Antiemetic Interactions

Nausea is the most common adverse event with bremelanotide, occurring in 40.0% of active-treatment patients vs. 1.3% on placebo in RECONNECT 1. This rate decreases with repeated dosing. Patients frequently ask about prophylactic antiemetic use.

Ondansetron (Zofran): 5-HT3 antagonist. No pharmacokinetic interaction. Ondansetron is an oral tablet subject to bremelanotide's gastric emptying delay. If used prophylactically, the orally disintegrating tablet (ODT) formulation absorbed via the buccal mucosa bypasses this issue. Alternatively, patients can take ondansetron 30 minutes before bremelanotide injection.

Metoclopramide: a prokinetic and D2 antagonist. Metoclopramide accelerates gastric emptying, directly opposing bremelanotide's GI-slowing effect. This may partially restore normal absorption kinetics of co-administered oral drugs, but no clinical study has confirmed this. D2 antagonism could theoretically blunt bremelanotide's dopaminergic pro-sexual effects downstream, though clinical relevance is unknown.

Prochlorperazine and promethazine: phenothiazine antiemetics with anticholinergic properties. These may worsen the constipation and dry mouth occasionally reported with bremelanotide. Ondansetron is preferred when antiemetic prophylaxis is warranted.

Clinical Decision Framework: Interaction Risk Tiers

| Risk tier | Drug class | Action required | |---|---|---| | Labeled interaction | Naltrexone (any dose) | Separate dosing by at least 4 hours; monitor for amplified nausea and flushing | | Labeled interaction | Narrow therapeutic index oral drugs | Separate dosing by at least 1 hour before or 4 hours after bremelanotide | | Pharmacodynamic caution | Antihypertensives, triptans, ergots, sympathomimetics | Blood pressure monitoring during initial co-use cycles | | Theoretical concern | Full opioid agonists, buprenorphine/naloxone | Possible attenuation of bremelanotide efficacy; counsel patient | | No interaction expected | SSRIs, SNRIs, bupropion, statins, ACE inhibitors, ARBs, oral contraceptives | No dose or timing adjustments needed |

Renal and Hepatic Impairment: Indirect Interaction Relevance

Bremelanotide AUC increases by 70% in women with severe renal impairment (eGFR <30 mL/min/1.73 m²) and by 78% in women with moderate hepatic impairment (Child-Pugh B) 4. While these are not drug-drug interactions per se, they amplify every interaction described above. Higher bremelanotide exposure means a larger gastric emptying effect, a greater pressor response, and more pronounced nausea. In these populations, the threshold for monitoring co-administered medications should be lower.

The prescribing information does not recommend dose reduction in renal or hepatic impairment but does recommend limiting use to the approved 1.75 mg dose and the 8-dose-per-month maximum 4.